HEMO-GE.ApS: Financial statements 2023
CVR: 39076322
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
HEMO-GE.ApS (CVR 39076322) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK -5,150 and a net result of DKK 2,514,622 compared with DKK 124,096 the year before. Equity in the 2023 report amounted to DKK 4,395,892. The solvency ratio was 99.9%.
- Gross Profit
- DKK -5,150
- Profit/Loss
- DKK 2,514,622
- Equity
- DKK 4,395,892
- Total Assets
- DKK 4,402,256
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | -5 t. | 2.5 mio. | 4.4 mio. | - |
| 2022 | - | -6 t. | 124 t. | 2 mio. | - |
| 2021 | - | -4 t. | 96 t. | 2 mio. | - |
| 2020 | - | -4 t. | 96 t. | 2.1 mio. | - |
| 2019 | - | -4 t. | -5 t. | 2.1 mio. | - |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
HEMO-GE.ApS has published its annual report for 2022. Gross profit came to DKK -5,813, and the net result was DKK 124,096.
About HEMO-GE.ApS
HEMO-GE.ApS is a Danish company of the type Anpartsselskab based in Rudkøbing, founded in 2017. The company is registered under the industry Ikke-finansielle holdingselskaber. The management consists of Henrik Graakjær Eriksen. The company is owned by Henrik Graakjær Eriksen. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK -6,000 and a net result of DKK 90,958 compared with DKK 96,416 the year before. Equity in the 2025 report amounted to DKK 4,326,266.